Blood Test Plus Digital Cognition Screen Detects Alzheimer's With 90% Accuracy
A UK partnership combines a blood biomarker test with digital cognitive assessment to catch Alzheimer's earlier and more accurately than typical GP diagnosis.
Summary
C2N Diagnostics has partnered with Cambridge Cognition and The Alzheimer's Trust to roll out an integrated Alzheimer's diagnostic pathway across the UK. The system pairs C2N's PrecivityAD2 blood test — which measures amyloid and phospho-tau protein ratios using high-resolution mass spectrometry — with Cambridge Cognition's CANTAB digital cognitive assessments and a national phlebotomy and MRI network. The combined approach reportedly detects Alzheimer's disease with around 90% accuracy, compared to roughly 70% for standard GP assessment. Published validation data in Nature Medicine supports the dual-biomarker strategy. The initiative targets long NHS diagnostic delays, aiming to give patients earlier access to accurate diagnoses and, by extension, earlier treatment and care planning.
Detailed Summary
Early and accurate Alzheimer's diagnosis is one of the most pressing unmet needs in brain health, directly affecting how quickly patients access treatments and how effectively they can plan care. This partnership between C2N Diagnostics, Cambridge Cognition, and The Alzheimer's Trust represents a significant step toward scalable, community-level diagnosis in the UK.
The centerpiece is C2N's PrecivityAD2 blood test, which uses high-resolution mass spectrometry to quantify Aβ42/Aβ40 ratios and the percentage of phosphorylated tau at position 217 (%p-tau217). These two biomarkers reflect amyloid plaque burden and tau pathology — the hallmark biological changes of Alzheimer's disease — and are combined algorithmically into an Amyloid Probability Score 2. The test received MHRA registration in 2025 and subsequent FDA clearance, giving it regulatory standing on both sides of the Atlantic.
When the blood test is paired with Cambridge Cognition's CANTAB Pathway digital cognitive assessments, validation analyses and a Nature Medicine study indicate combined detection accuracy of approximately 90%. This compares favorably to the roughly 70% accuracy typical of standard GP assessment, suggesting the integrated pathway could meaningfully reduce missed and delayed diagnoses.
Practically, UK healthcare professionals will be able to order both the blood test and the cognitive screen through The Alzheimer's Trust, which provides the phlebotomy and MRI infrastructure. This lowers the barrier to access and could substantially shorten the NHS diagnostic odyssey many patients currently endure.
Caveats apply. The 90% accuracy figure comes from validation analyses cited by the company, and independent real-world performance data in unselected UK primary care populations is still needed. Cost, reimbursement pathways, and NHS commissioning decisions will determine how broadly the test reaches patients. Still, combining a validated blood biomarker with a standardized digital cognitive tool represents a meaningful advance for brain-health monitoring as populations age.
Key Findings
- PrecivityAD2 plus digital cognitive testing detects Alzheimer's with ~90% accuracy vs ~70% for standard GP assessment.
- PrecivityAD2 measures Aβ42/Aβ40 and %p-tau217 via mass spectrometry, generating an Amyloid Probability Score.
- The test holds MHRA registration (2025) and FDA clearance, giving it dual regulatory standing.
- UK clinicians can now order both the blood test and CANTAB cognitive screen through a single national infrastructure.
- The partnership directly targets long NHS diagnostic wait times for Alzheimer's disease.
Methodology
This is a news report based on a company announcement made on World Alzheimer's Day. Evidence cited includes a Nature Medicine validation study and regulatory clearances, but the article does not provide independent peer-reviewed analysis or detailed methodology. Claims originate primarily from C2N Diagnostics.
Study Limitations
Accuracy figures are company-cited and may not reflect performance in unselected primary care populations; the Nature Medicine study should be reviewed independently. NHS adoption depends on reimbursement and commissioning decisions not addressed in this announcement. No head-to-head data against established PET or CSF biomarker standards is provided.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: